InsiderSignal.AI

InsiderSignal.ai

ALMS - Alumis Inc.

Insider Purchase by Tananbaum James B. (Dir, 10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Tananbaum James B., serving as Dir, 10% owner at Alumis Inc. (ALMS), purchased 72,212 shares at $7.38 per share, for a total transaction value of $532,925.00. Following this transaction, Tananbaum James B. now holds 15,778,040 shares of ALMS.

The trade was executed on Friday, November 21, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, November 25, 2025, 4 days after the trade was made.

Alumis Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Tananbaum James B.

Dir, 10%

James B. Tananbaum, M.D., M.B.A. is an independent Class II Director at Alumis Inc. (ALMS), serving since January 2021 and as a member of the Compensation Committee.[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum) Age 62, he holds significant ownership (~15.8%) through Foresite Capital-affiliated funds, reflecting his recent insider trading activity as Director, 10%.[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum) Tananbaum is the founder, President, and CEO of Foresite Capital Management, a U.S.-focused healthcare investment firm established in 2011 with ~$3.5B in assets under management, and co-founder of Foresite Labs.[[2]](https://foresitelabs.com/about/jim-tananbaum-md/)[[4]](https://www.foresitecapital.com/people/jim-tananbaum/) Tananbaum's career highlights include co-founding GelTex Pharmaceuticals (1991, acquired by Sanofi-Genzyme for $1.6B), serving as founding CEO of Theravance, Inc. (1997, spun into Innoviva and Theravance Biopharma with combined market cap exceeding $4B), and co-founding/managing director roles at Prospect Venture Partners (2000–2010).[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum)[[2]](https://foresitelabs.com/about/jim-tananbaum-md/)[[4]](https://www.foresitecapital.com/people/jim-tananbaum/) Earlier, he was a partner at Sierra Ventures and senior product manager at Merck.[[5]](http://web.mit.edu/hst/35_dev/profiles/tananbaum.html) He holds an M.D. and M.B.A. from Harvard, and B.S. in Applied Math and B.S.E.E. from Yale.[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum)

View full insider profile →

Trade Price

$7.38

Quantity

72,212

Total Value

$532,925.00

Shares Owned

15,778,040

Trade Date

Friday, November 21, 2025

93 days ago

SEC Filing Date

Tuesday, November 25, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Alumis Inc.

Company Overview

No company information available
View news mentioning ALMS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/1692894

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime